Previous 10 | Next 10 |
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities underway with an initial focus on a registration-directed trial in melanoma as step one to lever...
2023-10-09 01:33:58 ET Summary Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks include high competition in T-cell therapies, potential dilution from EPS of -$0.34, and an 11.11% sho...
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors PR Newswire Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. ...
2023-09-11 07:24:59 ET More on Immatics, Moderna, etc. Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Moderna: Buy Before The Fall Covid-19 Wave Moderna Falling As Vaccine Hesitancy Rises Moderna, Inc. ( MRNA ) Q2 2023 Earnings C...
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA technology for the development of novel cancer vaccines Collaboration to...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-17 08:02:33 ET More on Immatics Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203 Immatics Is Increasingly Becoming Interesting Immatics climbs 8% on $35M investment by Bristol Myers Squibb Immatics climbs 30% after early Phase...
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-tr...
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient enrollment for IMA402 Phase 1/2 trial underway The trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or re...
2023-07-24 18:21:28 ET Summary Bristol-Myers Squibb Company made a $35 million equity investment into Immatics N.V. The partnership with Bristol-Myers Squibb brought $15 million opt-in payment; Immatics also is eligible to earn up to $490 million in milestone payments in addition ...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...